Canada Alzheimer’s Therapeutics Market Report 2022 to 2030

Canada Alzheimer’s Therapeutics Market Analysis

$ 3999

Canada Alzheimer’s therapeutics market was valued at $384 Mn in 2022 and is estimated to reach $771 Mn in 2030, exhibiting a CAGR of 9.1% during the forecast period. The rising prevalence of Alzheimer's disease and the approval of therapies that modify the illness are expected to propel the market's growth. Biogen, Eisai, Roche, Novartis, Pfizer, Eli Lilly, Johnson & Johnson, AbbVie, AstraZeneca and Lundbeck are top leading pharmaceutical companies that are presently operating in the market

ID: IN10CAPH431 CATEGORY: Pharmaceuticals GEOGRAPHY: Canada AUTHOR: Medha Sansanwal

Buy Now

Canada Alzheimer’s Therapeutics Market Executive Summary

Canada Alzheimer’s therapeutics market was valued at $384 Mn in 2022 and is estimated to reach $771 Mn in 2030, exhibiting a CAGR of 9.1% during the forecast period.

Alzheimer's is a neurological condition that impairs thinking, behaviour, and memory. It typically starts slowly, gets worse over time, and affects a person's capacity to perform daily tasks. Nerve cells in Alzheimer's disease die as a result of abnormal alterations in the brain, such as the buildup of plaques and tangles. Alzheimer's disease does not currently have a cure. However,certain drugs can help control symptoms and enhance the quality of life. These medications, which include memantine, rivastigmine, and donepezil, relieve memory and cognitive issues by controlling specific chemicals in the brain. Additionally, non-drug approaches, including keeping a healthy lifestyle, being cognitively and socially engaged, and having a supportive environment, might contribute to improved overall management of the illness.

Over 402,000 seniors in Canada who are 65 years of age or older are living with dementia, representing a 7.1% prevalence rate. Remarkably, women make up almost two thirds of seniors in Canada who suffer from dementia. An incidence rate of 14.3 new cases per 1,000 seniors with dementia results from the approximately 76,000 new cases of dementia that are diagnosed annually. When compared to men, the incidence is higher in women. The age standardized prevalence of dementia has witnessed a considerable 21.2% increase. Almost half (48.4%) of Canadians with dementia who were 35 years of age or older reported having fair or poor general health, and nearly one-third (29.7%) reported having mental problems. Increased overall disability and particular functional impairments were strongly associated with dementia, 58.4% of those with dementia reported reduced mobility, and 37% reported moderate to severe pain and discomfort. Additionally, over half (56.8%) experienced urinary incontinence, and almost one-third (31.7%) reported bowel incontinence. According to estimates, males with dementia may lose an average of 16.0 years of fully functional life owing to disability and early mortality, compared to an average loss of 15.2 years for women.

Health Canada's approval of Lecanemab (Leqembi) in January 2023 marked a significant advancement in the treatment of Alzheimer's disease. First approved in Canada to treat the underlying cause of Alzheimer's disease, this ground-breaking medication was developed by Eisai and Biogen and targets amyloid plaques in the brain. However, its effectiveness is primarily observed in patients in the early stages of the disease.

In a recent study, Eli Lilly's Donanemab, showed encouraging findings with a 60% reduction in cognitive deterioration and focused on amyloid plaques. There are worries about the possible cost and accessibility of this medication, which is presently being reviewed by Health Canada.

Market Dynamics

Market Growth Drivers

Aging population: The aging population is a major factor affecting the Alzheimer's treatment drug market in Canada. According to Statistics Canada, the number of people 65 and older will nearly double to 26.4 million by 2037. Due to the increased incidence of Alzheimer's disease in this age group, there is a rising demand for more treatment options.

Growing awareness: The surge in awareness and advocacy initiatives, including public campaigns by Alzheimer's organizations such as the Alzheimer Society of Canada, is producing heightened public demand for improved accessibility to treatment alternatives for Alzheimer. The market for Alzheimer's therapy drugs has the opportunity to develop as more people become aware of the disease.

Approval of new drugs: The market is expected to grow as a result of the recent approval of Lecanemab (Leqembi) in Canada and the upcoming approvals of medications like Donanemab, which offer hope for better treatments.

Market Restraints

High Drug Prices: Alzheimer's drugs that have recently been developed, such lecanemab, are quite expensive. Concerns over patient' financial viability are raised, and the burden on provincial health insurance programs may result in limitations on coverage and patient accessibility.

Limited long-term efficacy: All currently available drugs, including those that have been developed recently like Lecanemab, primarily aim to delay the onset of symptoms rather than offer a complete cure. Certain people are wary of spending a lot of money on treatments because they are unsure about their long-term effectiveness and impact on the progression of the illness.

Limited coverage: Accessibility discrepancies based on patient characteristics and geographic regions are often caused by limitations within provincial health insurance schemes that leave these costly medications underinsured. Lower-income individuals and families are typically disproportionately affected by this financial burden.

Notable Recent Updates

March 2021, Eisai Co., Ltd. and Biogen Inc. extended their current collaboration agreement to address Alzheimer's disease.
March 2019, US FDA gave Zydus Cadila permission to sell their transdermal rivastigmine system, which is used to treat Alzheimer's disease.

Healthcare Policies and Regulatory Landscape

Health Canada is the national regulatory organization responsible for guaranteeing the quality, safety, and effectiveness of medications and other healthcare goods in Canada. New drugs must pass a rigorous evaluation process and be examined and authorized by Health Canada before they can be marketed and sold in Canada. This is done to ensure their safety and efficacy.

The part of Health Canada that is specifically in charge of drug regulation is the Pharmaceutical Drugs Directorate (previously the Therapeutic Products Directorate). Drug applications are reviewed by the PDD for quality, safety, and efficacy.

Competitive Landscape

Key Players

Biogen
Eisai
Roche
Novartis
Pfizer
Eli Lilly
Johnson & Johnson
AbbVie
AstraZeneca
Lundbeck

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Canada Alzheimer’s Therapeutics Market Segmentation

By Type

Early-Onset Alzheimer's
Late-Onset Alzheimer's
Familial Alzheimer's disease

By Drug Name

Donepezil
Rivastigmine
Memantine
Galantamine
Manufactured a combination of memantine and donepezil

By Drug Class

Cholinesterase Inhibitors
NMDA Receptor Antagonists
Manufactured Combination

By End-Users

Hospitals
Specialty Clinics
Homecare
Others

By Distribution Channel

Hospital pharmacies
Drug stores
Retail pharmacies
Online pharmacies
Other distribution channel

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.